ICVTS Click here for other ICVTS advertising opportunities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Interact CardioVasc Thorac Surg 2008;7:235-239. doi:10.1510/icvts.2007.161356
© 2008 European Association of Cardio-Thoracic Surgery

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Haydar Yasa
Cengiz Ozbek
Ali Gurbuz
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yakut, N.
Right arrow Articles by Gurbuz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yakut, N.
Right arrow Articles by Gurbuz, A.
Related Collections
Right arrow Peripheral vascular

Institutional report - Vascular general

The influence of levosimendan and iloprost on renal ischemia–reperfusion: an experimental study

Necmettin Yakut, Haydar Yasa*, Banu Bahriye Lafci, Ragip Ortac, Engin Tulukoglu, Murat Aksun, Cengiz Ozbek and Ali Gurbuz

Department of Cardiovascular Surgery, Atatürk Education and Research Hospital, Izmir, Turkey

Received 2 July 2007; received in revised form 3 October 2007; accepted 4 October 2007

*Corresponding author. 2/11 sok. No: 7 D: 18 Oyak Sitesi, Izmir, Turkey. Fax: +90 232 2434848.

E-mail address: hyasa20{at}yahoo.com (H. Yasa).


    Abstract
 Top
 Abstract
 1. Introduction
 2. Material and methods
 3. Results
 4. Discussion
 5. Conclusions
 References
 
The effects of iloprost on ischemia–reperfusion injury have been studied on the skeletal, muscle, liver, myocardium, kidney, and spinal cord. However, no sufficient data exist about effects of levosimendan on renal ischemia–reperfusion injury. The purpose of this experimental study was to investigate and compare effectiveness of levosimendan and iloprost on renal injury induced by ischemia and reperfusion. Fifty rabbits were divided into five groups. Levosimendan was continuously infused starting half an hour before the cross-clamp. Cross-clamp time was one hour. After one hour ischemia, levosimendan was continued for 4 h in Group A whereas Group B took iloprost in the same protocol. Group C was the control group which did not receive any medication. Group D was sham group and Group E was medicated both iloprost and levosimendan. Renal tissues were histologically and biochemically evaluated. The histological scores were obtained according to presence of tubuler necrosis and atrophy, regenerative atypia, hydropic degeneration (Group A vs. Group C<0.001, Group B vs. Group C<0.001, Group D vs. Group C<0.01, Group E vs. Group C<0.001). Mean malondialdehyde levels were 114±12 nmol/g tissue; in Group A 121±13 nmol/g tissue, in Group B 134±13 nmol/g tissue, in Group E 130±11 nmol/g tissue, in Group D 134±11 nmol/g tissue (Group A vs. Group B; P=0.003, Group B vs. Group D; P=0.132, Group A vs. Group E; P=0.132). Malondialdehyde levels and histologic scores of all of the groups were significantly different from the control group. Iloprost and pentoxyfillin reduced renal ischemia–reperfusion injury in rabbit model. There was no significant difference between these two medications.

Key Words: Iloprost; Levosimendan; Ischemia/reperfusion injury; Rabbit kidney


    1. Introduction
 Top
 Abstract
 1. Introduction
 2. Material and methods
 3. Results
 4. Discussion
 5. Conclusions
 References
 
Reperfusion of a previously ischemic organ triggers a cascade, collectively termed ischemia–reperfusion injury that leads to production of reactive oxygen species and causes to massive secretion of systemic inflammatory mediators [1, 2]. The effects of ischemia–reperfusion can result in development of the systemic inflammatory response syndromes and multiple organ dysfunctions, both of which account for 30–40% of the mortalities in the intensive care units [3, 4].

Iloprost, a stable prostacyclin analog was shown to decrease neutrophil activation and aggregation beside inhibition of oxygen-free radical production and release of lysosomal enzymes [5, 6].

Levosimendan is a recently synthesized positive inotropic drug which improves myocardial contraction without increasing calcium concentration in myocardial cells and has also a vasodilating effect by opening adenosine triphosphate-sensitive potassium channels [7]. It was reported that a single dose levosimendan administration seems to have anti-inflammatory and anti-apoptotic properties, reducing circulating proinflammatory cytokines and soluble apoptosis mediators [8]. The effects of iloprost on ischemia–reperfusion injury have been studied on the skeletal, muscle, liver, myocardium, kidney, and spinal cord [5, 6, 9]. However, no sufficient data exist about effects of levosimendan on renal ischemia–reperfusion injury.

The purpose of this experimental study was to investigate and compare effectiveness of levosimendan and iloprost on renal injury induced by ischemia and reperfusion.


    2. Material and methods
 Top
 Abstract
 1. Introduction
 2. Material and methods
 3. Results
 4. Discussion
 5. Conclusions
 References
 
2.1. Animal preparation

After approval of the study by the local animal care committee, experiments were performed on 50 New Zealand white rabbits of both sexes, each weighing approximately 3 kg. Anesthesia was induced by intramuscular ketamine (50 mg/kg) and xylasine; then followed by 25 mg/kg fractionally as needed during the intervention to allow for spontaneous respiration, and without endotracheal intubation. A catheter (24 gauge) was placed in an ear vein to give maintenance fluid of 0.9% NaCl (20 ml/h). An arterial catheter (20 gauge) was placed in an ear artery to monitor blood pressure (Petas Kma 375). The room temperature was kept between 28–30 °C. The experiment was done according to the ethics of Pamukkale University Medical School, Denizli, Turkey. The study was funded by the authors.

2.2. Study groups and operative technique

Animals were randomly allocated into five groups each consisting of ten rabbits. The experiment was continued until ten animals in each group survived during the entire procedure and postoperative 4 h. In Group A, rabbits received a loading dose of 25 µg/kg levosimendan over 15 min, followed by a continuous infusion of 0.1–0.2 mg/kg/min ceased after renal artery declamping. In Group B, iloprost was infused at a rate of 25 ng/kg/min at the same period. A similar value of saline solution was given in the control group, Group C correspondingly. In sham Group D, the operation was performed in the same fashion, but without artery occlusion, in Group E, both iloprost and levosimendan were infused simultaneously.

After sterile surgical preparation, a midline laparotomy was performed, and the abdominal aorta was reached through a transperitoneal approach. The left renal artery was mobilized from the aorta. Each animal was anticoagulated with 150 U/kg heparin intravenously. Renal ischemia was induced by clamping the artery with an arterial bulldog clamp. The clamp was removed after 60 min and restoration of blood flow was verified visually.

Abdominal layers were closed and catheters were removed. When the animals awakened from anesthesia, they were taken to their cages. A total of four animals died during the procedure, one at the anesthesia induction, and three in surgical intervention. They were excluded from the study. After 4 h reperfusion, left nephrectomy was done and renal biopsies were taken from the cortex of the kidneys for microscopic, histological and biochemical evaluation.

2.3. Histopathologic evaluation

After the last 4th hour reperfusion, animals were anesthetized with intramuscular ketamine, 50 mg/kg in dose, and euthanized by intravenous administration of a high concentration of potassium (K).

Portions of the fixed renal biopsy materials were examined microscopically (Nikon model Eclipse E600W). The specimens were fixed in 10% formalin. Paraffin blocks were cut at 5 µm and stained with hematoxylin-eosin. Microscopic renal injury was considered in the presence of tubuler necrosis and atrophy, regenerative atypia, hydropic degeneration, interstitial fibrosis, loss of supranuclear cytoplasms and brush border disappearance. Renal injury was scored semiquantatively according to these characteristics as; grade 0 as normal, grade 1 as mild (focal), grade 2 as moderate (multifocal) and grade 3 as severe (diffuse) pathologic chances (Tables 3, 4) by the same pathologist, who was blinded to the study [23].


View this table:
[in this window]
[in a new window]

 
Table 3 Histopathological scoring

 

View this table:
[in this window]
[in a new window]

 
Table 4 Histopathologic results

 
2.4. Tissue MDA analysis

Lipid peroxidation measurement was measured from the renal cortical malondialdehyde (MDA) content as Uchiama and Mihara described [24]. Renal cortical tissues were homogenized by using Ultra-Turrax T25 homogenisator in 1.15% ice-cold potassium chloride solution containing 50 ml/l of Triton X-100. A 0.5 ml homogenate was mixed with 3 ml of 1% phosphoric acid and 1 ml of 0.6% thiobarbituric acid. The mixture was heated on boiling water for 45 min. After addition of 4 ml of n-butanol, the contents were centrifuged at 4000 gyration per minute for 10 min. The upper organic layer absorbance was measured at 532 nm spectrophotometrically. The tissue MDA levels were expressed as nmoles per gram renal tissue.

2.5. Statistical analysis

Statistical analysis was done with SPSS 10.0 statistical software program (SPSS Inc, Chicago, IL). Continuous variables were expressed as the mean±1 S.D. Differences between the experimental and control groups were analyzed for their statistical significance by use of the two-tailed Student t-test. The P-values <0.05 were considered to be statistically significant.


    3. Results
 Top
 Abstract
 1. Introduction
 2. Material and methods
 3. Results
 4. Discussion
 5. Conclusions
 References
 
There were no statistically significant differences in the physiological parameters between five groups in preischemic and postischemic periods. Hemodynamic variables of all five groups are shown in Table 1. Preischemic and postischemic mean arterial pressure was minimally lower in iloprost and levosimendan group when compared with control group. Levosimendan was well tolerated in all animals, and mean arterial pressure decreased by 8% from baseline. There was no significant alteration in the heart rate recordings. Table 2 shows mean values and S.D. of pH, pO2, pCO2, HCO3. Blood pH, pO2, and HCO3 levels of medicated groups were found significantly higher than the levels of control group.


View this table:
[in this window]
[in a new window]

 
Table 1 End of the procedure hemodynamic parameters

 

View this table:
[in this window]
[in a new window]

 
Table 2 Mean values and S.D. of pH, pO2, pCO2, HCO3

 
Histological evidence of reperfusion injury was the presence of tubuler necrosis and atrophy, regenerative atypia, hydropic degeneration, interstitial fibrosis, loss of supranuclear cytoplasms and brush border disappearance. The mean histopathologic scores of Group A, B, and D, E were significiantly lower than the control group (Group A vs. Group C; P<0.001, Group B vs. Group C; P<0.001, Group D vs. Group C; P<0.001, Group E vs. Group C; P<0.001, Group B vs. Group E; P=0.311, Group A vs. Group E; P=0.312). There was no significant differences between levosimendan and iloprost groups (P=0.315) (Table 4). The MDA levels of the medicated groups were significantly lower than the levels of the control group. Mean malondialdehyde levels were 114±12 nmol/g tissue; in Group A 121±13 nmol/g tissue, in Group B 134±13 nmol/g tissue, in Group E 130±11 nmol/g tissue, in Group D 134±11 nmol/g tissue (Group A vs. Group B; P=0.003, Group B vs. Group D; P=0.132, Group A vs. Group E; P=0.132). Fig. 1 demonstrates a normal renal histology whereas Figs. 24 demonstrate abnormal renal morphologies.


Figure 1
View larger version (146K):
[in this window]
[in a new window]

 
Fig. 1. A normal renal histology. Supranuclear cytoplasms in the tubuler epithelial cells are seen to be normal (H&E x200).

 

Figure 2
View larger version (149K):
[in this window]
[in a new window]

 
Fig. 2. Moderate degree ischemic tubullary renal injury which is characterized by vacuolization, loss of the ciliary epithelial margin (H&E x100).

 

Figure 4
View larger version (143K):
[in this window]
[in a new window]

 
Fig. 4. Severe, diffuse tubuler necrosis, brush border disappearance (H&E x100).

 
Mean MDA level was 35±6 nmol/g tissue in Group C (Group A vs. Group C; P<0.001, Group B vs. Group C; P<0.01, Group E vs. Group C; P<0.001, Group D vs. Group C P<0.001). This showed that the ischemia reperfusion model was well formed in the rabbits.


    4. Discussion
 Top
 Abstract
 1. Introduction
 2. Material and methods
 3. Results
 4. Discussion
 5. Conclusions
 References
 
The results did not confirm the primary hypothesis that levosimendan showed a better protection than iloprost. However, it was proven that levosimendan and iloprost significantly reduced the ischemia/reperfusion injury on the light microscopic basis. It can be said that levosimendan and iloprost significantly improved the ischemia/reperfusion injury in the renal tubules.

Reperfusion of a previously ischemic organ triggers a cascade, termed ischemia–reperfusion injury [10]. The reperfusion of endothelial cells results in production of reactive oxygen species, such as hydroxyl radicals, hydrogen peroxide, and superoxide anions, and causes an imbalance which in turn leads to secretion of a systemic inflammatory radical, such as interleukin-1, -8, platelet-activating factor and tumor-necrosis factor alpha [11]. The ischemia–reperfusion process results in leukocyte dependent micro-vascular dysfunction, leukocyte plugging, impaired endothelium-dependent dilatation, enhanced capillary fluid filtration, and plasma protein extravasations all of which affect distal organs [12]. Influence of this process on kidneys is an increase in vascular permeability, leading to the reduction of renal cortical blood flow [13]. Iloprost, a stable prostacyclin analog acts as membrane stabilization and inhibits neutrophil functions which are potential mediators of ischemia–reperfusion injury [9]. Iloprost also decreases white blood cell aggregation and adhesion to vascular endothelium superoxide radical production from stimulated canine and human neutrophils, and free radical formation in myocardium subject to ischemia–reperfusion injury [14]. Emrecan and co-workers reported that iloprost protected the kidneys against ischemia–reperfusion [15]. Our study also reveals that iloprost has a protective effect on kidneys after transient ischemia.

Levosimendan is a recently synthesized positive inotropic drug that improves myocardial contraction without increasing calcium concentration in myocardial cells and has also a vasodilatation effect by opening adenosine triphosphate-sensitive potassium channels [7]. It was reported that a single dose of levosimendan administration seems to have anti-inflammatory and anti-apoptotic properties, reducing circulating proinflammatory cytokines and soluble apoptosis mediators [8]. Animal studies have demonstrated that the vasodilatation by levosimendan may be partially related to lowering of intracellular free calcium through potential inhibition of phosphodiesterase III, calcium desensitization, or opening of adenosine triphosphate-sensitive potassium channels [15–18]. However, no sufficient data exist about the role of levosimendan on kidneys after ischemia–reperfusion.

Ischemia–reperfusion injury attributed to the development of reactive oxygen species mediated lipid peroxidation, and this process can be measured through its products like malondialdehyde (MDA) [19–22]. In this study, a cortical MDA level was significantly lower in iloprost and levosimendan groups than in control group. These low MDA levels in this recent study demonstrated that lipid peroxidation was avoided in the iloprost and levosimendan groups. There were no significant differences between iloprost and levosimendan treated groups.


    5. Conclusions
 Top
 Abstract
 1. Introduction
 2. Material and methods
 3. Results
 4. Discussion
 5. Conclusions
 References
 
According to our results, iloprost and levosimendan are useful therapeutic agents for the treatment of acute renal ischemic conditions.


Figure 3
View larger version (137K):
[in this window]
[in a new window]

 
Fig. 3. Severe, diffuse tubuler necrosis, congestion and the bleeding in the interstitium (H&E x100).

 


    References
 Top
 Abstract
 1. Introduction
 2. Material and methods
 3. Results
 4. Discussion
 5. Conclusions
 References
 

  1. Adams JG Jr, Dhar A, Shukla SD, Silver D. Effect of pentoxifillin on tissue injury and platelet – activating factor production during ischemia–reperfusion injury. J Vasc Surg 1995;21:742–748.[CrossRef][Medline]
  2. Troyer-Caudle J. Reperfusion injury. J Vasc Nurs 1993;11:76–79.[Medline]
  3. Sucu N, Unlu A, Tamer L, Aytacoglu B, Coskun B, Bilgin R, et al. Effects of trimetazidine on tissue damage in kidney after hindlimb ischemia–reperfusion. Pharmacol Res 2002;46:345–349.[CrossRef][Medline]
  4. Neary P, Redmond HP. Ischemia-reperfusion injury and the systemic inflammatory response syndrome, Grace PA, Mathie RT, (editors): Ischemia–reperfusion injury. London: Blackwell Science; 1999:123–136.
  5. Fantone JC, Marasco WA, Elgas LJ, Ward PA. Stimulus specifity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. Am J Pathol 1984;115:9–16.[Abstract]
  6. Simpson PJ, Mitsos SE, Ventura A, Gallagher KP, Fantone JC, Abrams GD, Schork MA, Lucchesi BR. Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J 1987;113:129–137.[CrossRef][Medline]
  7. Follath F, Cleland JG, Just H, Steering Committee, Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double blind trial. Lancet 2002;360:196–202.[CrossRef][Medline]
  8. Parissis J, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kryzopoulos S, Iliodromitis E, Kremastinos D. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004;93:1309–1312.[CrossRef][Medline]
  9. Emrecan B, Tulukoglu E, Bozok S, Kestelli M, Onem G, Kupelioglu A, Yagdi S, Gurbuz A. Effects of iloprost and pentoxyfillin on renal ischemia–reperfusion in rabbit model. Eur J Med Res 2006;11:1–5.[Medline]
  10. Crinnion JN, Homer-Vanniasinkam S, Gough MJ. Skeletal muscle reperfusion injury: pathophysiology and clinical considerations. Cardiovasc Surg 1993;1:317–324.[Medline]
  11. Mazzone A, Mazzucchelli I, Fossati G, Gritti D, Girola S, Canale C, et al. Iloprost effects on phagocytes in patients suffering from ischaemic diseases: in vivo evidence for down regulation of {alpha}Mβ2 integrin. Eur J Clin Invest 1996;26:860–866.[Medline]
  12. Carden DL, Granger DL. Pathophysiology of ischemia–reperfusion injury. J Pathol 2000;190:255–266.[CrossRef][Medline]
  13. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000;95:3781–3787.[Abstract/Free Full Text]
  14. Belkin M, Wright JG, Hobson RW. Iloprost infusion decreases skeletal muscle ischemia–reperfusion injury. J Vasc 1990;11:77–83.
  15. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden I-B. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859–1866.[CrossRef][Medline]
  16. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium smooth sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999;288:316–325.[Abstract/Free Full Text]
  17. Yokoshiki H, Katsube Y, Sunagawa M, Speralakis N. Levosimendan, a novel Ca sensitizer, activates the glibenclamide-sensitize K channel in rat arterial myocytes. Eur J Pharmacol 1996;333:249–259.[CrossRef]
  18. Kertsen JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000;90:5–11.[Abstract/Free Full Text]
  19. Cetinkale O, Bilgi;alc L, Bolayirli M, Sengül R, Ayan F, Burcak G. Involvement of neutrophils in ischemia–reperfüsion injury of inguinal island skin flaps in rats. Plast Reconstr Surg 1998;102:153–160.[CrossRef][Medline]
  20. Lindsay T, Romaschin A, Walker PM. Free radical mediated damage in skeletal muscle. Microcirc Endothelium Lymphatics 1989;5:157–170.[Medline]
  21. McCord JM. The evaluation of free radicals and oxidative stress. Am J Med 2000;108:652–659.[CrossRef][Medline]
  22. Draper HH, Hadley M. Malonaldehyde determination as index of lipid peroxidation. In: Parker L, Glazer A, (editors): Methods in enzymology. New York: Academic Press; 1991, 186, 421–431.
  23. Onal A, Astarcioglu H, Ormen M, Atila K, Sarioglu S. The beneficial effect of L-carnitine in rat renal ischemia–reperfusion injury. Ulus Travma Dergisi 2004;10:160–167.
  24. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978;86:271–278.[CrossRef][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Haydar Yasa
Cengiz Ozbek
Ali Gurbuz
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yakut, N.
Right arrow Articles by Gurbuz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yakut, N.
Right arrow Articles by Gurbuz, A.
Related Collections
Right arrow Peripheral vascular


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS